In vitro antibacterial activity of solithromycin (CEM-101) against macrolide-resistant (n=62) 45
Streptococcus agalactiae (group B streptococcus, GBS) is a common cause of severe infections in 71 neonates, such as sepsis and meningitis. It is also an important pathogen causing bacteremia and 72 endocarditis in elderly patients, patients with diabetes, and in immunocompromised subjects (1, 2) . 73
The highest GBS mortality and morbidity result from invasive infections in neonates, particularly in 74 those with very low-birth weight (3, 4). Due to the severity of disease resulting from S. agalactiae 75 infections in neonates, elderly, diabetics, and immunocompromised patients, the United States 
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To overcome the macrolide resistance of Gram-positive cocci, the ketolides, which are macrolide 95 analogs, were developed to treat respiratory infections due to microorganisms (Streptococcus 96 pneumoniae, Streptococcus pyogenes) that are macrolide resistant. 97
Telithromycin was the first ketolide introduced as the drug able to address the macrolide resistance 98 problem and received FDA approval in 2004. However, because of severe adverse events (9, 10), it 99 is only approved for use in community-acquired bacterial pneumoniae (CABP). 100
Solithromycin (CEM-101) is a novel fluoroketolide that shows activity comparable or superior to 101 telithromycin, azithromycin, erythromycin and clarithromycin with high potency against Gram-102 positive and Gram-negative bacteria, as well as activity against most macrolide-resistant bacteria 103 (11-13). It is currently being evaluated in a Phase 3 trial as monotherapy for CABP. 104
The aim of this study was to evaluate the in vitro activity of solithromycin against a spectrum of S. incubated at 37°C for 18 to 24h in aerobic conditions. GBS was selected by the production of a pink 118 pigment when grown aerobically on ChromID streptoB agar. GBS identification was performed by 119 means of the VITEK tm system (bioMérieux). 120
Capsular gene typing 121
The capsular genotype Ia, Ib, II-IX of S. agalactiae was identified by a multiplex PCR assay as 122 previously described (14). DNA was extracted from each strain using a DNeasy kit (Qiagen) . 123
Approximately 1 ng of DNA was used in the PCRs with primers and conditions as described 124 elsewhere (14). Serotypes of strains were identified by analyzing the unique banding pattern 125 following agarose gel 1.5% (wt/vol) electrophoresis. 126
Alpha-like protein (Alp) genes 127
The alpha-like protein genes bca, alp1 (Epsilon), alp2/3, Rib, and alp4 in the strains were detected 128 by using a multiplex PCR as already described (15 
Antimicrobial agents and MIC determination 146
Solithromycin (CEM-101) was obtained from Cempra, Inc., Chapel Hill, NC. Determination of 147 minimal inhibitory concentration (MIC) was carried out using the microdilution broth method 148 according to CLSI guidelines (21). In brief, an inoculum of approximately 5 x 10 5 -5 x 10 6 CFU/ml 149 was incubated with a concentration of solithromycin ranging from 0.008 to 4 μg/ml. S. pneumoniae 150 ATCC 49619 was used as a quality control. Results were observed after 18 h of incubation at 37°C. 151
For comparison to solithromycin, penicillin, azithromycin, clarithromycin and erythromycin were 152 used. The Etest method (Liofilchem, Italy) was used for all of the reference antibiotics. The test was 153 performed according to the manufacturer's instructions. Antibiotic concentrations ranged from 154 0.002 to 32 μg/ml for penicillin and from 0.016 to 256 μg/ml for azithromycin, clarithromycin and 155
erythromycin. Erythromycin was also tested by an automated microdilution broth method (Vitek2, 156 Biomérieux). The concentrations ranged from 0.25 to 8 μg/ml. Breakpoint interpretation was done 157 according to EUCAST guidelines (22) and it was as follows: penicillin, ≤0.25 and >0.25 μg/ml, 158 susceptible and resistant, respectively; erythromycin, azithromycin and clarithromycin, ≤0.25 and
Statistical analysis 163
The χ2 test was used to evaluate the differences in distributions of surface proteins, serotypes, 164 genotypes and phenotypes. A P value of < 0.05 was considered significant and a P value of <0.01 165 was considered highly significant. 
MICs of antimicrobial agents for clinical strains 169
The activities of solithromycin and the comparator antimicrobial agents against clinical strains are 170 shown in Table 1 . The MIC 50 and the MIC 90 of solithromycin were ≤0.008 and 0.015 μg/ml against 171 erythromycin-susceptible strains, which were respectfully at least 4-fold and 3-fold lower than that 172 of penicillin, the first line agent both for intrapartum antibiotic prophylaxis and for the treatment of 173 GBS infections in adults. On the other hand, erythromycin and clarithromycin had a MIC 50 and a 174 MIC 90 comparable to that of penicillin, while azithromycin had both a MIC 50 and MIC 90 of ≤0.125 175 μg/ml. Against erythromycin-resistant strains, solithromycin had a MIC 50 of 0.03 μg/ml and a 176 MIC 90 of 0.125 μg/ml. The MIC 50 of penicillin was 0.032 and comparable to that of solithromycin, 177 whereas the MIC 90 of penicillin was 2.7-fold lower than solithromycin against erythromycin-178 resistant strains. 179
Evaluation of macrolide-resistant genotypes and phenotypes of GBS 180
The determination of macrolide-resistant genotypes in GBS was performed to evaluate the 181 differences in the activities between solithromycin and the other antimicrobial agents tested. Strains with the L phenotype had a MIC distribution between ≤0.008 and 0.015 μg/ml for 205 solithromycin and between 0.023 and 0.047 μg/ml for penicillin (Figure 1) . 206
The majority of the erm(B) gene carrying strains of S. agalactiae showed high resistance (MIC>256 207 μg/ml) to clarithromycin and azithromycin. In contrast, solithromycin showed a MIC 90 of 208 0.06 μg/ml against these same strains ( Table 2 ). The MIC 90 of solithromycin against mef(A/E) 209 strains was 0.125 μg/ml, whereas the MIC 90 for ermB gene carrying strains was two-fold lower 210 (0.06 µg/mL). 211
Capsule serotyping and the alp family genes 212
The detection of genes encoding particular capsular serotypes was performed by multiplex PCR. 213
Overall, the most represented serotypes isolated were types V (n=40, 55.5%), III (n=12, 16.6%) and 214
Surface proteins of GBS are likely to play an important role in the pathogenesis of S. agalactiae 218 infection, therefore they were evaluated by PCR. The presence of a particular alp gene in relation to 219 the serotype was noted (Table 3) . 220
Of the 30 alp2-3 -positive strains isolated, 25 were of serotype V; 14 of 22 epsilon-positive strains 221 corresponded to serotype V, and 6 corresponded to serotype Ia; rib-positive strains were present in 222 almost all serotypes isolated. Conversely, a certain serotype commonly corresponded to a particular 223 MICs than susceptible strains, the solithromycin MIC for macrolide-resistant GBS rarely exceeds 265 0.125 μg/ml. These lower MICs suggest that this drug may be useful in the treatment of infections 266 caused by these pathogens. There were five isolates of the cMLS B phenotype that had both erm(A) 267 subclass erm(TR) and erm(B) genes; the coexistence of both genes has been documented previously 268 (32) . Furthermore, three isolates that displayed cMLS B phenotypes harboured both mef(A/E) genes 269 as well as erm(B) genes and one isolate that had the iMLSB phenotype had both erm(A) subclass 270
erm(TR) and mef(A/E) genes. This finding implies differential gene expression as only the erm(B) 271
gene and erm(TR) gene were expressed in the different isolates, respectively. Exceptionally and for 272 the first time, to our knowledge, we found one strain that harboured all three macrolide resistance 273 genes and displayed the cMLS B phenotype. 274 We observed that all of the GBS strains that had the iMLS B phenotype and harboured the erm(B) or 275 the erm(A) (subclass ermTR) genes expressed low-level resistance to erythromycin (MICs 1-12 276 μg/ml), but high azithromycin MICs in absolute terms (2 ->256μg/ml). This unusual resistance 277 pattern has been previously identified in macrolide-resistant S. pyogenes strains harbouring the 278 erm(A) gene with point mutations in the erm(A) regulatory region leading to constitutive methylase 279 expression (33). Whether or not this was the case for the strains isolated in this study requires 280 further evaluation. 281
Further, we identified five macrolide-susceptible strains that contained the erm(B) or erm(TR) 282 genes or both, as has been reported previously (16). Whether it is possible for these susceptiblestrains carrying macrolide resistance genes to become resistant upon environmental stimulus or over 284 time is unknown. 285
It has been hypothesized previously that the spread of strains of particular surface protein profiles 286 and serotypes reflects the selection of the best evolutionary lineages by the immune system (34). In 287 this study we found that our isolates presented serotype-surface protein gene combinations 288 (serotype V-alp2,3; serotype III-rib) already reported (34, 35) and a different combination 289 (serotype Ia-epsilon) that we observed in a previous study ( 
